The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway
CONCLUSION: This study demonstrates for the first time that the novel hydroxamic acid-based HDAC inhibitor YPX-C-05 produces significant antihypertensive and vasodilatory effects through the PI3K/Akt/eNOS pathway. Our findings support the developing prospect of YPX-C-05 as a novel antihypertensive drug.PMID:38052330 | DOI:10.1016/j.vph.2023.107251 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 5, 2023 Category: Drugs & Pharmacology Authors: Pan-Pan Pang Hao Sun Pei-Xia Yu Wei-Min Yang Yong-Tang Zheng Xun Li Chang-Bo Zheng Source Type: research
The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway
CONCLUSION: This study demonstrates for the first time that the novel hydroxamic acid-based HDAC inhibitor YPX-C-05 produces significant antihypertensive and vasodilatory effects through the PI3K/Akt/eNOS pathway. Our findings support the developing prospect of YPX-C-05 as a novel antihypertensive drug.PMID:38052330 | DOI:10.1016/j.vph.2023.107251 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 5, 2023 Category: Drugs & Pharmacology Authors: Pan-Pan Pang Hao Sun Pei-Xia Yu Wei-Min Yang Yong-Tang Zheng Xun Li Chang-Bo Zheng Source Type: research
The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway
CONCLUSION: This study demonstrates for the first time that the novel hydroxamic acid-based HDAC inhibitor YPX-C-05 produces significant antihypertensive and vasodilatory effects through the PI3K/Akt/eNOS pathway. Our findings support the developing prospect of YPX-C-05 as a novel antihypertensive drug.PMID:38052330 | DOI:10.1016/j.vph.2023.107251 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 5, 2023 Category: Drugs & Pharmacology Authors: Pan-Pan Pang Hao Sun Pei-Xia Yu Wei-Min Yang Yong-Tang Zheng Xun Li Chang-Bo Zheng Source Type: research
Sex differences in vascular endothelial function related to acute and long COVID-19
Vascul Pharmacol. 2023 Dec 1:107250. doi: 10.1016/j.vph.2023.107250. Online ahead of print.ABSTRACTThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has been at the forefront of health sciences research since its emergence in China in 2019 that quickly led to a global pandemic. As a result of this research, and the large numbers of infected patients globally, there were rapid enhancements made in our understanding of Coronavirus disease 2019 (COVID-19) pathology, including its role in the development of uncontrolled immune responses and its link to the development of endotheliitis and endothelial dysfu...
Source: Vascular Pharmacology - December 3, 2023 Category: Drugs & Pharmacology Authors: Kitselman A Kayla J érôme Bédard-Matteau Simon Rousseau Reza Tabrizchi Daneshtalab Noriko Source Type: research
Unvealing organ-specific endothelial heterogeneity and its dysfunction
Vascul Pharmacol. 2023 Dec 1:107248. doi: 10.1016/j.vph.2023.107248. Online ahead of print.NO ABSTRACTPMID:38043759 | DOI:10.1016/j.vph.2023.107248 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 3, 2023 Category: Drugs & Pharmacology Authors: Rosalinda Madonna Source Type: research
Sex differences in vascular endothelial function related to acute and long COVID-19
Vascul Pharmacol. 2023 Dec 1:107250. doi: 10.1016/j.vph.2023.107250. Online ahead of print.ABSTRACTThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has been at the forefront of health sciences research since its emergence in China in 2019 that quickly led to a global pandemic. As a result of this research, and the large numbers of infected patients globally, there were rapid enhancements made in our understanding of Coronavirus disease 2019 (COVID-19) pathology, including its role in the development of uncontrolled immune responses and its link to the development of endotheliitis and endothelial dysfu...
Source: Vascular Pharmacology - December 3, 2023 Category: Drugs & Pharmacology Authors: Kitselman A Kayla J érôme Bédard-Matteau Simon Rousseau Reza Tabrizchi Daneshtalab Noriko Source Type: research
Unvealing organ-specific endothelial heterogeneity and its dysfunction
Vascul Pharmacol. 2023 Dec 1:107248. doi: 10.1016/j.vph.2023.107248. Online ahead of print.NO ABSTRACTPMID:38043759 | DOI:10.1016/j.vph.2023.107248 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 3, 2023 Category: Drugs & Pharmacology Authors: Rosalinda Madonna Source Type: research
Activated CTHRC1 promotes glycolysis in endothelial cells: Implications for metabolism and angiogenesis
Vascul Pharmacol. 2023 Nov 29;153:107246. doi: 10.1016/j.vph.2023.107246. Online ahead of print.ABSTRACTCTHRC1 is transiently expressed by activated fibroblasts during tissue repair and in certain cancers, and CTHRC1 derived from osteocytes is detectable in circulation. Because its biological activity is poorly understood, we investigated whether the N terminus of CTHRC1 encodes a propeptide requiring cleavage to become activated. The effects of full-length versus cleaved recombinant CTHRC1 on endothelial cell metabolism and gene expression were examined in vitro. Respirometry was performed on Cthrc1 null and wildtype mice...
Source: Vascular Pharmacology - December 1, 2023 Category: Drugs & Pharmacology Authors: Barbara H Toomey Sarah A Mitrovic Maia Lindner-Liaw Ruth G Leon Vazquez Doreen Kacer Sergey Ryzhov Igor Prudovsky Volkhard Lindner Source Type: research
Activated CTHRC1 promotes glycolysis in endothelial cells: Implications for metabolism and angiogenesis
Vascul Pharmacol. 2023 Nov 29:107246. doi: 10.1016/j.vph.2023.107246. Online ahead of print.ABSTRACTCTHRC1 is transiently expressed by activated fibroblasts during tissue repair and in certain cancers, and CTHRC1 derived from osteocytes is detectable in circulation. Because its biological activity is poorly understood, we investigated whether the N terminus of CTHRC1 encodes a propeptide requiring cleavage to become activated. The effects of full-length versus cleaved recombinant CTHRC1 on endothelial cell metabolism and gene expression were examined in vitro. Respirometry was performed on Cthrc1 null and wildtype mice to ...
Source: Vascular Pharmacology - December 1, 2023 Category: Drugs & Pharmacology Authors: Barbara H Toomey Sarah A Mitrovic Maia Lindner-Liaw Ruth G Leon Vazquez Victoria E DeMambro Doreen Kacer Sergey Ryzhov Igor Prudovsky Volkhard Lindner Source Type: research
Diabetes and vascular disease: New therapeutic avenues
Vascul Pharmacol. 2023 Nov 28:107247. doi: 10.1016/j.vph.2023.107247. Online ahead of print.ABSTRACTVascular disease remains a major burden for people with type 2 diabetes due to the syndromic nature of the disease. Therefore, strategies that go beyond the mere glycemic control need to be enacted. Recent evidence has been gathered showing the cardiorenal potential of medications such as glucagon-like peptide1-receptor agonists (GLP1RA) and sodium-glucose transporter 2-inhibitors (SGLT2i). Even greater are the expectations for the new dual glucose-dependent insulinotropic-peptide (GIP) and GLP1 agonists. Along with these ne...
Source: Vascular Pharmacology - November 30, 2023 Category: Drugs & Pharmacology Authors: Stefano Del Prato Source Type: research
Diabetes and vascular disease: New therapeutic avenues
Vascul Pharmacol. 2023 Nov 28:107247. doi: 10.1016/j.vph.2023.107247. Online ahead of print.ABSTRACTVascular disease remains a major burden for people with type 2 diabetes due to the syndromic nature of the disease. Therefore, strategies that go beyond the mere glycemic control need to be enacted. Recent evidence has been gathered showing the cardiorenal potential of medications such as glucagon-like peptide1-receptor agonists (GLP1RA) and sodium-glucose transporter 2-inhibitors (SGLT2i). Even greater are the expectations for the new dual glucose-dependent insulinotropic-peptide (GIP) and GLP1 agonists. Along with these ne...
Source: Vascular Pharmacology - November 30, 2023 Category: Drugs & Pharmacology Authors: Stefano Del Prato Source Type: research
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
CONCLUSIONS: Contemporary anticoagulation for acute PE includes parenteral agents in over 90% of patients; DOACs are used in the large majority of PE patients at discharge and their early use seems effective and safe also in selected intermediate-risk patients.TRIAL REGISTRATION NUMBER: NCT03631810.PMID:38013135 | DOI:10.1016/j.vph.2023.107245 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 28, 2023 Category: Drugs & Pharmacology Authors: Cecilia Becattini Giancarlo Agnelli Michele Diamanti Aldo P Maggioni Simone Vanni Francesco Dentali Iolanda Enea Paola Bortolotti Massimiliano De Vecchi Nicola Artusi Claudio Picariello Cinzia Nitti Donata Lucci Michele M Gulizia COPE Investigators Source Type: research
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
CONCLUSIONS: Contemporary anticoagulation for acute PE includes parenteral agents in over 90% of patients; DOACs are used in the large majority of PE patients at discharge and their early use seems effective and safe also in selected intermediate-risk patients.TRIAL REGISTRATION NUMBER: NCT03631810.PMID:38013135 | DOI:10.1016/j.vph.2023.107245 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 28, 2023 Category: Drugs & Pharmacology Authors: Cecilia Becattini Giancarlo Agnelli Michele Diamanti Aldo P Maggioni Simone Vanni Francesco Dentali Iolanda Enea Paola Bortolotti Massimiliano De Vecchi Nicola Artusi Claudio Picariello Cinzia Nitti Donata Lucci Michele M Gulizia COPE Investigators Source Type: research
Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death
CONCLUSIONS: Contemporary anticoagulation for acute PE includes parenteral agents in over 90% of patients; DOACs are used in the large majority of PE patients at discharge and their early use seems effective and safe also in selected intermediate-risk patients.TRIAL REGISTRATION NUMBER: NCT03631810.PMID:38013135 | DOI:10.1016/j.vph.2023.107245 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 28, 2023 Category: Drugs & Pharmacology Authors: Cecilia Becattini Giancarlo Agnelli Michele Diamanti Aldo P Maggioni Simone Vanni Francesco Dentali Iolanda Enea Paola Bortolotti Massimiliano De Vecchi Nicola Artusi Claudio Picariello Cinzia Nitti Donata Lucci Michele M Gulizia COPE Investigators Source Type: research
Efficacy and safety of tirofiban in patients with acute ischemic stroke treated with endovascular thrombectomy: A frequentist and Bayesian meta-analysis
CONCLUSION: For patients with AIS treated with EVT, tirofiban improved FFOs, decreased mortality, and did not increase SICH compared with controls; postbolus infusion for administering tirofiban was more favored than the bolus-only regimen.PMID:37992511 | DOI:10.1016/j.vph.2023.107244 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - November 22, 2023 Category: Drugs & Pharmacology Authors: Wei-Zhen Lu Hui-An Lin Sen-Kuang Hou Chyi-Huey Bai Sheng-Feng Lin Source Type: research
